Follicular dynamic and reproductive performance of gilts submitted to estrous cycle synchronization using two different progestogen sources

This study evaluated reproductive indicators of gilts treated with altrenogest or an intravaginal device (IVD) containing medroxyprogesterone acetate (MPA) for estrous cycle synchronization, starting the protocol on different days of the estrous cycle or replacing the IVD in the middle of treatment. In Experiment 1, 126 gilts were assigned, according to the day of treatment onset (Day 5 or 10 of the estrous cycle), to the following treatments: Control-5 (no hormone); Control-10 (no hormone); IVD-5 (IVD with MPA); IVD-10 (IVD with MPA); ALT-5 (altrenogest); or ALT-10 (altrenogest). The first day of the previous estrus was considered as Day 0 of the estrous cycle, and progestogen groups were treated for 14 d. In Experiment 2, 63 gilts were assigned to Control, ALT, or IVD groups. Progestogen treatment started on Day 10 of the estrous cycle, and the IVD was replaced after 7 d of treatment. In both experiments, no gilts expressed estrus during progestogen administration. In Experiment 1, the interval hormonal withdrawal-to-estrus (IHE) tended to be shorter when treatment started on Day 10 than on Day 5 (3.6 vs. 4.1 d, respectively; P = 0.09). The percentage of gilts expressing estrus after hormone withdrawal was lower for IVD-gilts (76.3%) compared to ALT (100%) and Control-gilts (92.9%; P ≤ 0.07). The percentage of persistent follicles (PFOL) was greater in IVD-10 (60.0%) and ALT-10 (33.3%) than CONT-10 (0.0%; P ≤ 0.06). The adjusted farrowing rate (AFR) was lower in IVD (65.5%) and ALT (80.5%) compared with CONT (97.4%; P ≤ 0.08). In Experiment 2, the IHE was longer for ALT than IVD (4.9 vs. 3.9 d, respectively; P < 0.01). No difference among groups was observed in the percentage of gilts expressing estrus (overall 86.4%), but the occurrence of PFOL was higher in IVD (61.5%) compared to ALT (5.3%), and Control groups (10.5%; P < 0.01). The AFR was lower in IVD (53.8%) than in ALT (88.2%) and Control (94.7%; P ≤ 0.05). The total number of piglets born was not affected by hormonal treatments in either experiment. Estrous expression was delayed in gilts treated with altrenogest or IVD-MPA. However, the reproductive performance of IVD-gilts was compromised, which was not circumvented by IVD replacement in the middle of treatment. Therefore, further studies are necessary to understand MPA pharmacodynamics and investigate alternative devices for a steady release of progestogens in gilts.

Effects of intravaginal devices containing different dosages of medroxyprogesterone acetate for the control of the estrous cycle in gilts

This aim of this study was to investigate the effectiveness of intravaginal devices (IVDs), containing medroxyprogesterone acetate (MPA), for controlling the estrous cycle in pubertal gilts. Gilts were assigned to four treatments: Control (no IVD); IVD containing 100 (IVD100), 200 (IVD200) or 400 mg (IVD400) of MPA. The IVDs were inserted on day 12 of the estrous cycle and maintained intra-vaginally for 14 days. The percentage of gilts in estrus, interval between IVD removal and estrous onset, adjusted farrowing rate (AFR), total number of piglets born (TPB), follicle size and serum progesterone (P4) were recorded. None of the gilts expressed estrus during the IVD treatment period. All gilts of the control group expressed estrus (15/15; 100%) which was greater (P =  0.03) than all IVD-treated gilts (33/44; 75%); however, there were no treatment differences (P =  0.09). The interval between IVD removal and estrous onset was shorter for IVD100 (3.8 ± 0.6 d) compared to IVD400 (5.3 ± 0.6 d; P = 0.05). The IVD400-treated gilts had smaller follicles than the IVD100-treated gilts (P =  0.05). The P4 concentrations were similar among treated groups (P =  0.99). The AFR did not differ among treatment groups (P = 0.37); however, the control group had a greater TPB than the other treatment groups (P =  0.04). The gilts treated with IVDs had longer interval to estrous expression. The most effective dosage was 400 mg of MPA, considering both the minimal follicular growth during the IVD treatment period and the lesser numbers of persistent follicles.